• Skip to main content
  • Skip to main content
Choose which site to search.
University of Arkansas for Medical Sciences Logo University of Arkansas for Medical Sciences
Psychiatric Research Institute
  • UAMS Health
  • Jobs
  • Giving
  • Clinical Care
    • AR ConnectNow
      • Frequently Asked Questions
      • Mental Health Resources
      • Substance Abuse Facilities
      • Contact AR ConnectNow
    • Center for Trauma Prevention, Recovery and Innovation
      • About Us
        • Collaborations
        • Our Team
      • In The Media
      • Resources
      • Training & Education
        • Education For The Public
        • Training For Professionals
      • What Is Trauma?
    • Child Study Center
      • Dialectical Behavior Therapy
      • Family Resources
        • Handouts for Parents
        • Books
        • Videos
      • Meet the Team
      • Treatment and Services
    • Interventional Psychiatry
      • Electroconvulsive Therapy
      • Esketamine
      • Ketamine Infusions
    • Neurodiversity Clinic
    • Northwest Arkansas Crisis Stabilization Unit
    • STRIVE
    • The Couples Center
      • Helping Couples Expand Their Love Capacities
      • Interdynamic Couples Therapy
      • SOS for Cabin Fever Couples
      • The Essentials of Sex Therapy
      • 2023 Training Opportunities and Certification Program with Chelsea Wakefield, Ph.D., LCSW
      • 2023 Training Schedule
    • Walker Family Clinic
      • Mental Health Resources
    • Women’s Mental Health Program
    • Center for Addiction Services and Treatment (CAST)
      • Improving Access To Treatment For Opioid Use Disorder
      • MATRIARC
        • Project ECHO
      • Medication and Counseling Treatment
      • Medications To Treat Opioid Use Disorders
      • Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
      • Suboxone Treatment Program
      • Subutex Treatment Program
      • What is Buprenorphine?
      • What Is Methadone?
      • What Is Naltrexone?
      • What Is Vivitrol?
      • Drugs and Addiction
      • Opioid Use Disorder
    • Inpatient Units
      • Child Diagnostic Unit
        • Child Diagnostic Unit Videos
      • Women’s Inpatient Unit – 5 North
    • Pulaski County Regional Crisis Stabilization Unit
      • Operation SAVE
    • Neuropsychology
    • Psychiatry Clinic in Fayetteville
  • Education
    • For Current Residents
  • Research
    • Center for Addiction Research
      • Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
      • What is Vivitrol?
      • Faculty
        • Alison Oliveto, Ph.D
        • Linda Larson-Prior, Ph.D.
        • Merideth Addicott, Ph.D.
        • Michael Mancino, M.D.
        • Nihit Kumar, M.D.
    • Center for Health Services Research
      • Behavioral Health QUERI
      • Health Services Research and Development Service
      • Rural Outreach Program
        • Rural Outreach Program Team
      • South Central (VISN 16) Mental Illness Research, Education and Clinical Center
      • Center for Health Services Research Faculty and Staff
        • Brandon J. Griffin, Ph.D.
        • Carolyn J. Greene, Ph.D.
        • Christopher Long, Ph.D.
        • Corey Hayes, Pharm.D., Ph.D., MPH
        • Eva Woodward, Ph.D.
        • Jacob Painter, Pharm.D, Ph.D.
        • Leah Tobey, PT, DPT, MBA
        • Marcela Weber, Ph.D.
        • Mary J. Bollinger, MPH, Ph.D.
        • Melissa J. Zielinski, Ph.D.
        • Michael Cucciare, Ph.D.
        • Michael Wilson, M.D., Ph.D., FAAEM, FACEP
        • Prasad R. Padala, M.D., M.S., FACHE
        • Rajinder “Sonia” Singh, Ph.D.
        • Sara J. Landes, Ph.D.
        • Traci Abraham, Ph.D.
        • Angie Waliski, Ph.D.
        • Ellen P. Fischer, Ph.D.
        • Geoffrey M. Curran, Ph.D.
        • Greer Sullivan, M.D., M.S.P.H.
        • Jeffrey M. Pyne, M.D.
        • JoAnn Kirchner, M.D.
        • Joy Reeves Pemberton, Ph.D.
        • Karen Drummond, Ph.D.
        • Kristen M. Viverito, Psy.D.
        • Puru Thapa, M.D., M.P.H.
        • Richard R. Owen, M.D.
        • Teresa Hudson, Pharm.D., Ph.D.
        • Teresa L. Kramer, Ph.D.
      • Postdoctoral Fellowship
        • CeMHOR/HSR&D
        • MIRECC
    • Health and the Legal System (HEALS) Lab
      • Projects in the Health and the Legal System (HEALS) Lab
    • Helen L. Porter and James T. Dyke Brain Imaging Research Center
      • Childhood Trauma Study
      • Directions to BIRC
      • Events
      • MRI Frequently Asked Questions
      • Prospective Collaborators
      • Prospective Participants
      • Prospective Trainees
      • Publications
      • Media
      • Resources
    • Neurocognitive Dynamics Laboratory
      • Current Studies
    • Neurodevelopmental Risk and Resilience Program
    • Research Trials
  • Patients and Visitors
    • Advisory Board
    • Art of the Psychiatric Research Institute
    • Mental Health Resources
    • Mission And Vision Statements
    • Positions at the Psychiatric Research Institute
    • Map and Directions
    • Faculty and Staff
    • Giving
  1. University of Arkansas for Medical Sciences
  2. Psychiatric Research Institute
  3. Clinical Care
  4. Center for Addiction Services and Treatment (CAST)
  5. What Is Vivitrol?

What Is Vivitrol?

VIVITROL is only available in one dose, 380 mg, and must be administered by a healthcare professional. It is given as a 4 mL gluteal intramuscular injection, delivering medication continuously over the approved dosing interval.

VIVITROL must not be given intravenously, subcutaneously, or into adipose tissue. Inadvertent subcutaneous injection of VIVITROL may increase the likelihood of severe injection site reactions

Injection Site Reactions

  • VIVITROL injections may be followed by pain, tenderness, induration, swelling, erythema, bruising, or pruritus; however, in some cases injection site reactions may be very severe.
  • Injection site reactions not improving may require prompt medical attention, including, in some cases, surgical intervention.
  • Select proper needle size for patient body habitus, and use only the needles provided in the carton.
  • Patients should be informed that any concerning injection site reactions should be brought to the attention of their healthcare provider.

VIVITROL is an extended-release microsphere formulation of naltrexone that delivers medication continuously over a one-month period (or 4 weeks).1

The recommended dose of VIVITROL is 380 mg, delivered intramuscularly once a month (every 4 weeks).

Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.

Dosage and Administration

Prior to initiating VIVITROL, an opioid-free duration of a minimum of 7–10 days is recommended for patients, to avoid precipitation of withdrawal that may be severe enough to require hospitalization.

VIVITROL is available in one dose, 380 mg, delivered intramuscularly every 4 weeks or once a month by a healthcare provider.

VIVITROL must not be administered intravenously or subcutaneously.

If a patient misses a dose, he/she should be instructed to receive the next dose as soon as possible.

Psychiatric Research Institute LogoPsychiatric Research InstitutePsychiatric Research Institute
Mailing Address: 4224 Shuffield Drive, Little Rock, AR 72205
Phone: (501) 526-8100
  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Pinterest
  • Disclaimer
  • Terms of Use
  • Privacy Statement

© 2023 University of Arkansas for Medical Sciences